

AT A GLANCE

Industry & Stage

- Biotech
- Oncology
- Early clinical stage

Fundraising Goals

- **Seed Round:** \$4 Million (Q2 2023)
- **Series A:** \$20 Million (Pending)

Board of Directors, Founders

& Management Team

- Yuji Otsuki, MD,PhD (Chairman & CEO)
- Hideyuki Saya, MD,PhD
- Osamu Nagano, DDS,PhD
- Nobuhiro Nishiyama, PhD
- Toru Natsume, PhD

Use of Funds

- **R&D (20%):** Working capital for R&D operations (staff, lab, equipment, consumables)
- **Business Development (5%):** Fundraising, partnering & licensing
- **Intellectual Property (5%):** Portfolio expansion, strategy & IP protection
- **General & Administrative (10%):** Operations & administrative overhead
- **Clinical Trials (60%):** Operations

Key Advisors

- **Corporate Counsel:**

Disclaimer


This executive summary contains forward-looking statements that include uncertainties and involve significant risk. The discovery, development, and commercialization of products described herein may differ materially from FerroptoCure, Inc.'s expectations. Although the information in this executive summary is accurate to the knowledge of FerroptoCure, Inc.'s management, the company does not make any representations or warranties, express or implied, as to the accuracy or completeness of the information contained herein. In making any investment decision, investors must conduct and rely on their own investigation of the company, its business, representations and warranties, if any, contained in any definitive agreements entered into with FerroptoCure, Inc.

FERROPTOCURE, INC.
EXECUTIVE SUMMARY: FERROPTOSIS

Company Overview & Team. FerroptoCure, Inc. is a biopharmaceutical company committed to the development of ferroptosis-inducing chemotherapy. FerroptoCure was established in May 2022 as a spin-off from Keio University with >100 published articles and contributions from **Dr. Hideyuki Saya, MD, PhD**, a worldwide expert in neurosurgery and cancer molecular biology with >60 published articles, **Dr. Osamu Nagano, DDS, PhD**, a worldwide expert in cancer molecular biology with >20 published articles.

Technology. FerroptoCure is developing ferroptosis-inducing anticancer drugs. In recent years, there has been a growing interest in the antioxidative system used by cancer cells, which helps prevent cell death caused by oxidative stress (ferroptosis). These systems significantly contribute to the survival of cancer cells and their resistance to treatment. As in any cell type, cancer cells depend on antioxidant system to regulate ferroptosis for survival. We found two targets that cancer cells use to prevent oxidative stress: xCT and ALDH work together collaboratively to suppress the oxidative stress. Using a synthetic lethality approach, we were able to strongly induce ferroptosis through the simultaneous inhibition of both xCT and ALDH. xCT

is also expressed in greater amounts in cancer cells than normal cells, therefore, we can induce ferroptosis specifically in cancer cells, with little damage to normal cells. In our development, we have confirmed a high antitumor effect and safety not only for Triple-Negative Breast Cancer (TNBC) but also for many treatment-resistant solid tumors. Furthermore, our approach involves the use of low molecular weight compounds, which eliminates the need for specialized and costly techniques such as cell therapy or antibody drugs.



Clinical Unmet Needs & Market Opportunities. It has been reported that poor treatment response and acquittance of resistance to chemotherapy are due to the antioxidant system. Thus, FerroptoCure has strategically prioritized TNBC, a \$671M market, as its first product with both high unmet clinical needs and high potential for combination with chemotherapy. However, FerroptoCure intends to expand its oncology pipeline to all solid cancers, resulting in a much larger \$200B market. For example, B-Cell Lymphoma represents an opportunity projected at \$9.2B by 2027 in the 7 major markets.

Competitive Analysis: There are three companies developing ferroptosis-inducing chemotherapy. Kojin Therapeutics is the first company who started to develop such therapeutic approach. Bridgebio and KUDA Therapeutics are also developing similar solutions. They are developing their drugs for renal cancer, but we are developing our drugs for all solid cancers because we were able to identify the deep mechanism that cancer cells use to avoid ferroptosis and leverage the benefits of synthetic lethality. Moreover, although they are still in R&D or preclinical phase, we already started a Phase1 study in Japan, and thus expect to reach full approval and patients first.

Pipeline. Our lead candidate (FC-001) was developed by drug repurposing and started a Phase I study in Japan in January 2024 for TNBC. We combined two existing oral drugs to target TNBC: Sulfasalazine, also used for ulcerative colitis, and Oxyfedrine, also used for angina pectoris. This offers low cost and high clinically proven safety. TNBC is common in young women, but these drugs have been shown to not influence fertility, making them safe for all women. FC-002 is currently being developed from an existing drug that is chemically improved for better drug delivery into solid tumors. We synthesized a polyethylene-glycol (PEG)-conjugated Sulfasalazine to use for solid cancers as an oral or injectable drug. FC-003 is being developed from a novel original compound for solid tumors. We already have some lead compounds and now are now testing the effect and safety with the hit compound.

Business Model & Exit Strategy. FerroptoCure's strategy is to focus on the clinical validation of its core technology, which is to specifically target tumors and induce ferroptosis. Beyond the clinical validation and economic benefits of launching its first product, FerroptoCure will also be poised for large and lucrative licensing deals with companies developing chemotherapies, who will benefit from a combination of their therapies with FerroptoCure's therapeutically-induced ferroptosis. Furthermore, the company will also be well positioned to develop its own combination approach. Hence FerroptoCure's exit strategy is to rapidly increase its valuation by establishing clinical POC, expanding its oncology pipeline, and securing partnering and licensing deals towards IPO or M&A exit scenarios within 5-6 years.